Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis.

ABSTRACT:

Background

The role of adding immune checkpoint inhibitors to chemotherapy in tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) remains unknown. We carried out a meta-analysis to comprehensively assess the role of chemoimmunotherapy combinations, with and without vascular endothelial growth factor (VEGF) inhibition, in TKI-resistant, EGFR-mutant NSCLC.

Materials and methods

We systemically searched PubMed/MEDLINE and the proceedings of key annual meetings between 2018 and 2024 to identify randomized studies that evaluated chemoimmunotherapy combinations and included patients with EGFR-mutant NSCLC. Six randomized, phase III trials (CheckMate-722, KEYNOTE-789, ORIENT-31, IMpower150, IMpower151, and ATT

SUBMITTER: Piotrowska Z 

PROVIDER: S-EPMC11381989 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature